Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials

Patients with heart failure (HF) have a high burden of symptoms and physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 (sodium-glucose cotransporter-2) inhibitors on these outcomes vary across the full range of EF remains unclear. METHODS: Patient-level data we...

Descripción completa

Detalles Bibliográficos
Autores principales: Nassif, Michael E., Windsor, Sheryl L., Gosch, Kensey, Borlaug, Barry A., Husain, Mansoor, Inzucchi, Silvio E., Kitzman, Dalane W., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Shah, Sanjiv J., Umpierrez, Guillermo, Austin, Bethany A., Lamba, Sumant, Khumri, Taiyeb, Sharma, Kavita, Kosiborod, Mikhail N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348645/
https://www.ncbi.nlm.nih.gov/pubmed/37203441
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.122.009837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348645/
https://www.ncbi.nlm.nih.gov/pubmed/37203441
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.122.009837

Ejemplares similares